As presented in this study, the main advantage for clinical use in quantitative point-of-care diagnostics utilizing the careSTARTTM G6PD biosensor is to provide a more accessible way of defining G-6-PD activity at bedside and identifying individuals with intermediate G-6-PD deficiency, especially in terms of differentiating heterozygous females. Here, G6PD is linked to hyperinsulinemic hypoglycemia, familial, 4.